Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.
Jamie P Dwyer, Noha Maklad, Ola Vedin...
https://pubmed.ncbi.nlm.nih.gov/40913594/Actively Recruiting
Led by AstraZeneca · Updated on 2026-09-25
5000
Participants Needed
771
Research Sites
N/A
Total Duration
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
CONDITIONS
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Baxdrostat plus dapagliflozin | Placebo plus dapagliflozin | Current standard care with dapagliflozin |
|---|---|---|---|
| What it is | Combination of baxdrostat, a selective aldosterone synthase inhibitor, plus dapagliflozin in adults with CKD and hypertension | Dapagliflozin plus matching placebo added to background ACE inhibitor or ARB in the same population | Dapagliflozin added to optimized standard care including ACE inhibitor or ARB is current guideline‑recommended therapy for CKD with hypertension |
| Role in trial | Investigational treatment arm | Randomized control arm | Represents usual care outside the trial |
| Primary use | Aims to reduce kidney failure, sustained decline in eGFR, heart failure events or cardiovascular death | Same composite endpoint as control arm | Used to slow CKD progression and improve kidney and cardiovascular outcomes |
| How it is given or performed | Oral baxdrostat plus oral dapagliflozin tablets taken concurrently | Oral dapagliflozin plus matching placebo tablet | Oral dapagliflozin added to ACE inhibitor or ARB |
| Evidence status | Efficacy under investigation in this ongoing Phase III trial in CKD with hypertension | Serves as internal control for evaluating efficacy | Evidence supports dapagliflozin improves kidney outcomes in CKD when added to ACE inhibitors or ARBs |
| Important risks | Risk of hyperkalemia and hypotension based on mechanism and class | Risks aligned with dapagliflozin alone | Known dapagliflozin risks include genital infections and volume depletion |
| Important limitations | Results not yet available; safety and kidney outcome effects unproven | As control arm, does not provide new evidence beyond standard dapagliflozin results | Guideline‑based use may not reflect hypertension‑specific CKD subgroup used in trial |
| Patient impact | Unknown patient outcome impact until trial results are available | No incremental benefit expected beyond standard dapagliflozin effect | Evidence shows benefit in delaying CKD progression and reducing cardiovascular events when used appropriately |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 4 weeks
Participants not currently treated with SGLT2 inhibitors will receive dapagliflozin for 4 weeks before randomization.
1 visit during this period
Duration - Up to 37 months
Participants are randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may be increased based on response.
Visits at 2, 4, 8, 16, 34, and 52 weeks, then approximately every 4 months
Duration - Up to several weeks after treatment
Once enough events have occurred, participants will have a final study close-out visit within 6 weeks. Participants who discontinue early will continue follow-up visits.
1 final visit within 6 weeks of study close
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jamie P Dwyer, Noha Maklad, Ola Vedin...
https://pubmed.ncbi.nlm.nih.gov/40913594/Emily K Yeung, Janani Rangaswami, Katherine R Tuttle...
https://pubmed.ncbi.nlm.nih.gov/42335037/AstraZeneca
Lead Sponsor